India

 Artemisia annua L. extracts inhibit the in vitro replication of SARS-CoV-2 and two of its variants.

Artemisia research for COVID-19 suggests its ability to inhibit and prevent virus replication. Lung diseases like COVID cause respiratory symptoms, including coughing, increased mucus, shortness of breath and congestion. Severe cases can cause pulmonary fibrosis. Current research suggests that an active ingredient, artemisinin, acts as an antiviral by inhibiting the host's TGF-B protein to block virus replication, as well as reducing respiratory symptoms caused by the disease.


Sources:

https://www.globenewswire.com/news-release/2021/03/01/2184106/0/en/MATEON-THERAPEUTICS-AND-WINDLAS-BIOTECH-PUBLISH-PULMOHEAL-CLINICAL-DATA-AGAINST-COVID-19-IN-PEER-REVIEWED-JOURNALS.html

https://doi.org/10.1101/2021.01.08.425825.

https://www.biospectrumindia.com/news/43/18148/windlas-biotech-mateon-therapeutics-launch-integrated-solution-for-respiratory-wellness-in-india.html

https://pulmoheal.com/